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Table. Primary outcomes of claudicant patients undergoing infrainguinal
bypass by smoking status
Outcomes
Smokers
(n ¼ 119), %
Nonsmokers
(n ¼ 91), % c2 P
Adjusted OR
(95% CI) P
MALE 21 11 .04 2.8 (1.1-7.4) .03
AFS 12 12 .91 1.2 (0.4-3.2) .8
Death 3 11 .03 0.3 (0.08-1.23) .09
Limb loss 10 1 .008 21.0 (1.5-292) .02
AFS, Amputation-free survival; CI, conﬁdence interval; MALE, major
adverse limb event; OR, odds ratio.
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Volume 60, Number 6 Abstracts 1715used to treat the endoleak in such patients, and the current series reports the
outcome of therapy in the Aneurysm Treatment Using the Heli-FX
EndoAnchor System Global Registry (ANCHOR).
Methods: During a 29-month period ending in July 2014, 201 pa-
tients were enrolled in ANCHOR and treated with EndoAnchors for imme-
diate type Ia endoleaks after endograft deployment (primary arm; n ¼ 109
[54.2%]) or type Ia endoleaks remote from EVAR (revision arm; n ¼ 92
[45.8%]). Patients were followed up for clinical outcomes over a mean of
15 6 6 months after EndoAnchor implantation. Computed tomography
(CT) images were reviewed by an independent core laboratory in 145 pa-
tients (72.1%) preoperatively and in 109 (54.2%) postoperatively (108
with contrast). Continuous variables were assessed with the Student t-test
and dichotomous variables with the Fisher exact test. Bonferroni corrections
were used for multiple comparisons.
Results: Aneurysms averaged 60 6 16 mm in maximum diameter,
with infrarenal neck length of 16 6 12 mm, infrarenal neck diameter of
28 6 6 mm, and infrarenal angulation of 37 6 17. Aortic necks were
<10 mm in length in 42.7% and <5 mm in 17.5% of patients. An average
of 6 6 2 and 7 6 3 EndoAnchors was implanted in the primary and revision
cases, respectively (P ¼ .003), with successful deployment and absence of
type Ia endoleak on completion angiography in 190 of 201 patients
(94.5%). Over mean follow-up of 15 6 6 months, all-cause mortality was
two of 200 (1.0%), with aneurysm-related reinterventions in 21 patients
(10.4%). There were 12 patients (6.0%) with endograft-related reinterven-
tions and 11 patients (5.5%) with EndoAnchor-related reinterventions, all
for type Ia endoleaks. There were no ruptures or open surgical conversions.
Core laboratory analysis identiﬁed endoleaks in 14 of 108 patients (13.0%)
with postoperative contrast CT studies; four of 60 in primary cases (6.7%),
and 10 of 48 in revisions (20.8%; P ¼ .043). The endoleak was evident on
the ﬁrst postoperative CT scan in all but one of these cases. Short neck pre-
dicted EndoAnchor failure; 18 6 13 mm vs 8 6 5 mm in those with and
without postoperative type Ia endoleaks, respectively (P < .001). Neck
length of 5 mm was evident in 39.1% of patients with 12-month CT scans;
sac enlargement (>5 mm) developed in 3.7% of patients.
Conclusions: EndoAnchors are successful in remediating type Ia
endoleaks in 87.0% of cases. Success was more frequent in patients treated
for endoleaks that were detected and treated at the time of the initial
EVAR compared with those identiﬁed and treated in follow-up. EndoAn-
chors should be considered as a potentially effective treatment option
when type Ia endoleak is encountered during or after EVAR.
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Introduction: Smoking cessation is one of the primary methods of
treating claudication. However, many patients receive revascularization for
claudication while still smoking. We examined regional data from the
Vascular Quality Initiative (VQI) database to evaluate the impact of smok-
ing on outcomes of revascularization in claudicants in the VQI.
Methods: With consent of the members of the Carolinas Vascular
Quality Group (CVQG) of the VQI, all cases entered in the infrainguinal
(INF) bypass, suprainguinal bypass, and peripheral vascular intervention
modules were reviewed from 2010 to 2012. Univariate analysis was used
to identify demographic and comorbid differences between active and non-
active smokers. Multivariable regression modeling was used to assess pri-
mary outcomes of major adverse limb event (MALE), amputation-free
survival (AFS), limb loss (LL), and death.
Results: We identiﬁed 730 active smokers and 636 nonactive smokers
undergoing revascularization for claudication. Mean follow-up was 247
(214) days. Active smokers were younger and had more chronic obstructive
pulmonary disease, but less diabetes, congestive heart failure, hypertension,
and statin use. Multivariable regression modeling showed no differences in
overall outcomes of MALE, AFS, and death between active and nonactive
smokers when all procedure modules were combined; active smokers were
more likely, however, to suffer limb loss (3% vs 11%; odds ratio [OR],
2.3; 95% conﬁdence interval [CI], 1.0-5.4; P ¼ .05). When we examined
the modules separately, there were no differences in outcomes between
active and nonactive smokers in peripheral vascular intervention (n ¼
1252 limbs) or suprainguinal bypass (n ¼ 122). Compared with nonactivesmokers, active smokers with claudication who received INF bypass had a
much higher odds of MALE (21% vs 11%; OR, 2.8; 95% CI, 1.1-7.4; P
¼ .03) and limb loss (10% vs 1%; OR, 21.0; 95% CI, 1.5-292; P ¼ .02),
but had no difference in death or AFS (Table).
Conclusions: Claudicants who undergo INF bypass while actively
smoking have increased odds of MALE and limb loss compared with non-
active smokers in the CVQG. ORs for limb loss and MALE are signiﬁcantly
higher than that of previously reported patients with claudication treated
with medical management. Before performing INF bypass on claudicants,
aggressive smoking cessation methods should be implemented.Author Disclosures: R. Vallabhaneni: None; C. A. Kalbaugh: None;M.
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Demographic Factors and Lesion Severity on Stent Patency
Amy Roach, Sebastian Larion, Chad Ammar, Colin Brandt, S. Sadie
Ahanchi, Jean Panneton, David Dexter. Eastern Virginia Medical School,
Norfolk, Va
Introduction: The aim of our study was to perform a large-scale
multivariate analysis to identify the demographic, anatomic, or procedural
factors that impact primary iliac stent patency.
Methods: A retrospective record review of iliac stenting from 2011 to
2013 was conducted. Index iliac stenting patients were identiﬁed by Cur-
rent Procedural Terminology codes 37220, 37221, 37222, and 37223. Dif-
ferences in demographic, anatomic, and procedural characteristics were
analyzed by univariate analysis between groups based on primary patency.
Variables that were considered signiﬁcant (P < .05) were brought forward
in the Cox regression multivariate analysis.
Results: A total of 224 patients (53% male) underwent primary iliac
artery stenting, and 319 limbs were analyzed. Average age was 66 years
(range, 38-93 years) and 57% were Caucasian. Indication for procedure
was 64% claudication, 23% rest pain, and 13% ulcer/gangrene. The cohort
included all TransAtlantic Inter-Society Consensus (TASC) classiﬁcations:
50% TASC A, 25% TASC B, 12% TASC C, and 13% TASC D. The treated
anatomic location was isolated external iliac artery (EIA) in 27%, isolated
common iliac artery (CIA) in 55%, and combined CIA/EIA in 18%. Inter-
vention distal to the iliac arteries was performed in 37% of the cohort. There
were no procedural-related mortalities. Kaplan-Meier analysis at 1 and
3 years revealed a primary patency of 86% and 51%, primary assisted patency
of 98% and 89%, and secondary patency of 99% and 90%. For those patients
with critical limb ischemia preprocedurally, limb salvage was 88% at 1 year.
By Kaplan-Meier analysis, primary patency at 1 year was 93% for Caucasian
patients vs 79% for non-Caucasian (P ¼ .001). One-year Kaplan-Meier pri-
mary patency was 76% in patients aged <60 years, 86% in patients aged 60-
70 years, and 97% in patients aged >70 years, with a signiﬁcant difference
among all groups (P < .001). Primary patency was signiﬁcantly different
for those with and without EIA occlusion (P < .001), with 1-year primary
patency by Kaplan-Meier analysis of 71% and 86%, respectively. Primary
patency was also signiﬁcantly different for those with and without aortic oc-
clusion (P ¼ .008), with 1-year patency of 84% and 87%, respectively. The
reentry device differed signiﬁcantly among groups (P ¼ .028), with 1-year
patency rates of 79% for reentry device use and 87% for those who did
not have reentry device. We evaluated ﬁve factors on multivariate analysis,
and three factors were identiﬁed to impact primary patency: Caucasian
race (HR, 0.517; 95% conﬁdence interval [CI], 0.313-0.852; P ¼ .01)
and older age at the time of procedure (HR, 0.945; 95% CI, 0.920-
0.971; P < .001) positively affected patency. EIA occlusion (HR, 2.352;
95% CI, 1.294-4.275; P ¼ .005) negatively affected primary patency. Aortic
occlusion and reentry device were no longer signiﬁcant in our multivariate
model.
